Patient demographics
| Patient | Skeletal AE | Age | Sex | Race | BMI | Tumor type and stage | Treatment Regimen | Bone Metastases? | Other irAEs |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Compression fractures of T6, T7, T10, T11, and T12; rib and pelvic fractures | 75 | M | C | 19 | MelanomaStage IV | Pembrolizumab | No | None |
| 2 | Compression fractures, T6–12, L1 | 52 | M | C | 27 | MelanomaStage IV | Nivolumab | Yes | None |
| 3 | Compression fracture, T11; lumbar osteomalacia | 58 | M | C | 29 | MelanomaStage IV | Pembrolizumab | No | None |
| 4 | Resorptive bone lesion, left shoulder | 60 | M | C | 24 | MelanomaStage IV | Ipilimumab/nivolumab | No | Pneumonitis, hypophysitis, inflammatory arthritis |
| 5 | Resorptive bone lesion, right wrist | 60 | F | C | 26 | Renal cell carcinomaStage IV | Nivolumab | Yes | Inflammatory arthritis |
| 6 | Resorptive bone lesion, right clavicle | 51 | M | C | 25 | Non small cell lung cancerStage II | Ipilimumab/nivolumab | Yes | Inflammatory arthritis |
(AE) Adverse event, (irAEs) Immune-related adverse events